Why Whole inactivated virus vaccine?
Tried and tested technology platform that cannot cause the disease
|
Inactivated vaccines are made from microorganisms that have been killed through physical or chemical processes. These killed organisms cannot cause the disease.
Multiple vaccines of this type are approved and available in the market (e.g. Polio, Hepatitis A, Rabies, etc.) WIV can be used in vulnerable populations (i.e., pregnant women, older and certain immunocompromised patients). Covid-19 WIV vaccines have already been produced and tested at scale in China, where millions of vaccinations have been given. Sinovac and Sinopharm's vaccines have been given Emergency Use Approval by the WHO. |
A long-term solution to virus mutations
|
WIV vaccines are more likely to remain effective and relevant even if antigens of the SARS-CoV-2 genome mutate; in contrast to single or bi-epitope based vaccines, such as mRNA and or Adenovirus vaccines.
|
Is a Whole Virion based vaccine
|
WIV vaccines contain the Nucleocapsid 'N' protein as well as the Spike, providing broader protection than vaccines based only on the Spike protein, and may provide protection against other Coronaviruses.
|
Stable and compatible with current distribution infrastructure
|
WIV vaccines are known to be more stable than live attenuated viral (LAV) vaccines and have shelf-life/storage compatible (fully-liquid; stable in 2-8 degree Celsius) with existing supply chains to ensure last-mile delivery.
|
A Vaccine of Choice:
* Reliable platform
* Better able to deal with viral mutations
* Meets WHO Target Product Profile
* Ease of administration fully-liquid
* Compatible with existing supply chains (2-to-8-degree Celsius)
* Protection without infection
* Outbreak response
* Antigen sparing adjuvant
* Highly scalable manufacturing process
* Reliable platform
* Better able to deal with viral mutations
* Meets WHO Target Product Profile
* Ease of administration fully-liquid
* Compatible with existing supply chains (2-to-8-degree Celsius)
* Protection without infection
* Outbreak response
* Antigen sparing adjuvant
* Highly scalable manufacturing process
IITRI present The Development of the Refana Delta Strain Covid Vaccine
AT THE AMERICAN SOCIETY OF VIROLOGY (ASV) CONFERENCE - JULY 2022
SAFE, EFFECTIVE, LOW COST COVID-19 VACCINE FOR ALL
Shape Divider - Style split